These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 19723143)

  • 1. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer.
    Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J
    Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.
    Sprenger T; Conradi LC; Beissbarth T; Ermert H; Homayounfar K; Middel P; Rüschoff J; Wolff HA; Schüler P; Ghadimi BM; Rödel C; Becker H; Rödel F; Liersch T
    Cancer; 2013 Jan; 119(1):26-35. PubMed ID: 22736392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
    Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Ioue Y; Miki C; Kusunoki M
    Ann Surg Oncol; 2009 Dec; 16(12):3488-98. PubMed ID: 19657699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
    Le H; Zeng F; Xu L; Liu X; Huang Y
    Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
    Jao SW; Chen SF; Lin YS; Chang YC; Lee TY; Wu CC; Jin JS; Nieh S
    Ann Surg Oncol; 2012 Oct; 19(11):3432-40. PubMed ID: 22739652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.
    Song W; Li H; Tao K; Li R; Song Z; Zhao Q; Zhang F; Dou K
    Int J Clin Pract; 2008 Aug; 62(8):1212-8. PubMed ID: 18479363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer.
    Kim ST; Sohn I; DO IG; Jang J; Kim SH; Jung IH; Park JO; Park YS; Talasaz A; Lee J; Kim HC
    Cancer Genomics Proteomics; 2014; 11(5):259-66. PubMed ID: 25331798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.
    Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A
    Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD133 expression is correlated with chemoresistance and early recurrence of gastric cancer.
    Lee HH; Seo KJ; An CH; Kim JS; Jeon HM
    J Surg Oncol; 2012 Dec; 106(8):999-1004. PubMed ID: 22674531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.
    Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A
    Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of CD133 and hypoxia inducible factor-1α gene expression in rectal cancer after preoperative chemoradiotherapy.
    Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Koike Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M
    Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):323-32. PubMed ID: 20970309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.
    Jing F; Kim HJ; Kim CH; Kim YJ; Lee JH; Kim HR
    Int J Oncol; 2015 Apr; 46(4):1582-8. PubMed ID: 25625240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of stem-cell markers OCT-4 and CD133: important prognostic factors in papillary renal cell carcinoma.
    Kim K; Ro JY; Kim S; Cho YM
    Hum Pathol; 2012 Dec; 43(12):2109-16. PubMed ID: 22944295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression of octamer-binding transcription factor 4A, prominin-1 and aldehyde dehydrogenase strongly indicates involvement in the initiation of lung adenocarcinoma resulting in shorter disease-free intervals.
    Cortes-Dericks L; Galetta D; Spaggiari L; Schmid RA; Karoubi G
    Eur J Cardiothorac Surg; 2012 Jun; 41(6):e173-81. PubMed ID: 22529186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Expression of Cancer Stem Cell Markers ALDH1 and CD133 in Various Lung Cancer Subtypes.
    Roudi R; Korourian A; Shariftabrizi A; Madjd Z
    Cancer Invest; 2015; 33(7):294-302. PubMed ID: 26046383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment CD133 and cyclooxygenase-2 expression as the predictive markers of the pathological effect of chemoradiotherapy in rectal cancer patients.
    Shinto E; Hashiguchi Y; Ueno H; Kobayashi H; Ishiguro M; Mochizuki H; Yamamoto J; Hase K
    Dis Colon Rectum; 2011 Sep; 54(9):1098-106. PubMed ID: 21825889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of expression of CD133 and Ki-67 in gastric cancer.
    Saricanbaz I; Karahacioglu E; Ekinci O; Bora H; Kilic D; Akmansu M
    Asian Pac J Cancer Prev; 2014; 15(19):8215-9. PubMed ID: 25339008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of CXCR4 and CD133 co-expression on the prognosis of patients with stage II~III colon cancer.
    Li XF; Guo XG; Yang YY; Liu AY
    Asian Pac J Cancer Prev; 2015; 16(3):1073-6. PubMed ID: 25735334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma.
    Xi HQ; Zhao P
    J Clin Pathol; 2011 Jun; 64(6):498-503. PubMed ID: 21415057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem cell marker CD133 affects clinical outcome in glioma patients.
    Zeppernick F; Ahmadi R; Campos B; Dictus C; Helmke BM; Becker N; Lichter P; Unterberg A; Radlwimmer B; Herold-Mende CC
    Clin Cancer Res; 2008 Jan; 14(1):123-9. PubMed ID: 18172261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.